© Globe Newswire
28.01.2026
SXTP
LISTED
NASDAQ
60 Degrees Pharmaceuticals Exercises License Option with Florida State University for Large-Scale Purification of Castanospermine for Non-Rx Use
News Preview
60 Degrees Pharma licenses FSU technology to purify castanospermine and begins U.S. regulatory steps for non-Rx Australian Chestnut Extract....
Themefolio
Profiler
Peergroup
© PR Newswire
28.01.2026
207940
LISTED
KOE
Samsung Biologics receives EcoVadis Platinum, the highest sustainability rating
News Preview
Ranked in the top one percent among more than 150,000 companies assessed globallyRecognized for strengthened sustainability management across all four assessment categoriesINCHEON, South Korea, Jan. 28, 2026 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), announced that it h...
Themefolio
Profiler
Peergroup
© PR Newswire
28.01.2026
INSM
LISTED
NASDAQ
Insmed to Present Multiple Abstracts on Treprostinil Palmitil Inhalation Powder (TPIP) at Pulmonary Vascular Research Institute (PVRI) 2026 Congress
News Preview
—Abstracts Include the Phase 3 PALM-PAH Study Design, a Presentation of the Previously Disclosed Topline Phase 2b PAH Data, a Functional Respiratory Imaging Analysis from the Phase 2b Study in Pulmonary Arterial Hypertension (PAH), and Pulmonary Vasodilation Data in Rat Models—BRIDGEWATER, N.J., Jan. 28, 2026 /PRNewswire/ -- Insmed Incorporated (N...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© PR Newswire
28.01.2026
LSL
LISTED
TSX
LSL PHARMA GROUP SUCCESSFULLY OBTAINED U.S. FDA CERTIFICATION FOR THE MANUFACTURING OF OPHTHALMIC OINTMENTS FOR COMMERCIALIZATION IN THE UNITED STATES
News Preview
Approval enables access to the U.S. market and supports future growth opportunitiesBOUCHERVILLE, QC, Jan. 28, 2026 /CNW/ - LSL PHARMA GROUP INC. (TSXV: LSL) (The "Corporation" or "LSL Pharma"), a Canadian integrated pharmaceutical company, is pleased to announce that it has secured certification from the U.S. Food and Drug Administration (FDA) for...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
23.01.2026
© PR Newswire
28.01.2026
CALC
LISTED
NASDAQ
CalciMedica Announces Discontinuation of Phase 2 KOURAGE Trial in AKI Following Independent Data Monitoring Committee Recommendation
News Preview
Safety concern warrants reevaluation of study design, including enrollment criteriaPotential future trial with Auxora™ in AKI to be evaluated after data analysisLA JOLLA, Calif., Jan. 28, 2026 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium releas...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.01.2026
ITGR
LISTED
NYSE
Integer to Highlight Integrated R&D Solutions and Expanded Coating Capabilities During MD&M West 2026
News Preview
Attendees Invited to Experience Integer’s New Booth #3201 Attendees Invited to Experience Integer’s New Booth #3201...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.01.2026
BNTX
LISTED
NASDAQ
BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer
News Preview
BioNTech appoints Kylie Jimenez as CPO, effective March 1, 2026, to drive global people strategy supporting its 2030 multi-product oncology vision....
Themefolio
Profiler
Peergroup
© BusinessWire
28.01.2026
MSCL
LISTED
TSX
Satellos Announces Share Consolidation in Connection with Proposed Nasdaq Listing
News Preview
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announces that the Company has completed a consolidation of its outstanding common shares (the “Common Shares”) on the basis of one post-consolidat...
Themefolio
Profiler
Peergroup
© BusinessWire
28.01.2026
GKOS
LISTED
NYSE
Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR
News Preview
Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved an NDA labeling supplement allowing for re-administration of iDose® TR using a repeat...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.01.2026
OKYO
LISTED
LSE
OKYO Pharma Announces Successful Type C Meeting with the FDA
News Preview
FDA confirms Phase 2b/3 clinical design, including primary endpoint, sample size and development approach FDA confirms Phase 2b/3 clinical design, including primary endpoint, sample size and development approach...
Themefolio
Profiler
Peergroup
© PR Newswire
28.01.2026
HALO
LISTED
NASDAQ
Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance
News Preview
Updates Preliminary Unaudited 2025 Estimates:- Total Revenue of $1,385 - $1,400 million, YoY Growth of 36% to 38%1- Royalty Revenue of $865 - $870 million, YoY Growth of 51% to 52%1Raises 2026 Financial Guidance Ranges: - Increases Total Revenue to $1,710 - $1,810 million, YoY Growth of 23% to 30%2 - Increases Royalty Revenue to $1,130 - $1,170 mi...
Themefolio
Profiler
Peergroup
© PR Newswire
28.01.2026
TECH
LISTED
NASDAQ
Bio-Techne Launches Simple Plex Ultra-Sensitive Assays on Ella Platform to Enable Femtogram-Level Detection of Neurological Biomarkers
News Preview
Detects low-abundance proteins in blood at femtogram concentrations for earlier disease insightsSupports research in Alzheimer's, ALS, MS, Parkinson's Disease, and Traumatic Brain Injury with validated biomarkersAutomated immunoassay workflow reduces variability; total runtime is under three hoursMINNEAPOLIS, Jan. 28, 2026 /PRNewswire/ -- Bio-Tech...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
28.01.2026
VERA
LISTED
NASDAQ
Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer
News Preview
Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.01.2026
BIIB
LISTED
NASDAQ
Biogen’s Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options
News Preview
CAMBRIDGE, Mass., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for litifilimab (BIIB059) for the treatment of cutaneous lupus erythematosus (CLE). Litifilimab is a first in-class, humanized IgG1 monoclonal antibody (mAb)...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.01.2026
BCT
LISTED
TSX
BriaCell Patients’ Images Show Regression and Resolution of Metastasized Tumors and Immune Activation
News Preview
PHILADELPHIA and VANCOUVER, British Columbia, Jan. 28, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, releases new images highlighting resolution of metastatic breast...
Themefolio
Profiler
Peergroup
© PR Newswire
28.01.2026
DHR
LISTED
NYSE
Danaher Reports Fourth Quarter and Full Year 2025 Results
News Preview
WASHINGTON, Jan. 28, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the fourth quarter and full year 2025. All results in this release reflect only continuing operations and period-to-period comparisons are year-over-year unless otherwise noted.
Key Fourth Quarter 2025 ResultsNet earnings were $1....
Themefolio
Profiler
Peergroup
© Globe Newswire
28.01.2026
RANI
LISTED
NASDAQ
Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer
News Preview
SAN JOSE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the promotion of Alireza Javadi, Ph.D., to Chief Technical Officer....
Themefolio
Profiler
Peergroup
© Globe Newswire
28.01.2026
VREO
LISTED
CSE
Vireo Growth Inc. Enters into Non-Binding Memorandum of Understanding to Acquire The Hawthorne Gardening Company from ScottsMiracle-Gro
News Preview
Planned share-based transaction is expected to be completed during the first fiscal quarter of 2026...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.01.2026
INDV
LISTED
NASDAQ
Indivior to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Webcast on February 26ᵗʰ
News Preview
RICHMOND, Va., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will report its fourth quarter and full-year 2025 financial results on Thursday, February 26, 2026, at 7:00 a.m. U.S. EST. Following the release of the financial results, Joe Ciaffoni, Chief Executive Officer, and other members o...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.01.2026
TEVA
LISTED
TLV
Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential
News Preview
Q4 and FY 2025 Highlights:...
Themefolio
Profiler
Peergroup
© BusinessWire
28.01.2026
ANTM
LISTED
NYSE
Elevance Health Reports Fourth Quarter and Full Year 2025 Results; Sets Full Year 2026 Outlook
News Preview
Elevance Health, Inc. (NYSE: ELV) reported fourth quarter and full year 2025 results.
"Elevance Health delivered fourth quarter results in line with our outlook, reflecting disciplined execution in a dynamic environment. As we enter 2026, our focus is on advancing affordability and making healthcare easier to access and navigate for the members...
Themefolio
Profiler
Peergroup
© PR Newswire
28.01.2026
2096
LISTED
XETRA
Boehringer Ingelheim und Simcere gehen Partnerschaft ein, um eine dual-zielgerichtete Antikörperbehandlung zur Behandlung von entzündlichen Darmerkrankungen voranzutreiben
News Preview
Neuartiger bispezifischer Antikörper TL1A/IL23p19 zielt auf die Auslöser der Krankheitspathogenese ab, um die Wirksamkeitsgrenze bei entzündlichen Darmerkrankungen zu überwinden. Lizenz- und Kooperationsvereinbarung stärkt Boehringers Pipeline für Entzündungskrankheiten mit einem potenziellen, erstklassigen, präklinischen Wirkstoff.Boehringer erhä...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.01.2026
JUNS
LISTED
NASDAQ
Jupiter Neurosciences Expands Nugevia™ Addressable Market with Focus on GLP-1 Users
News Preview
Nugevia™ supports metabolic, mitochondrial, and neuroinflammatory biology impacted by GLP-1-driven weight loss...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.01.2026
SAILIFE
LISTED
BSE
Mabtech and Sai Life Sciences Announce Strategic Collaboration to Advance Immunology Research with EYRA Platform at Sai Boston Site
News Preview
BOSTON and STOCKHOLM, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Mabtech, a global life science tools company specializing in advanced immunoassays, and Sai Life Sciences, a leading integrated Contract Research, Development, and Manufacturing Organization (CRDMO), today announced a strategic collaboration that establishes Sai’s Boston laboratory as a co-m...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.01.2026
DXSP
LISTED
AQXE
DXS International plc (AQSE: DXSP): Half-year Financial Report
News Preview
DXS INTERNATIONAL PLC...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
28.01.2026
MDCE
LISTED
OTC
Medical Care Technologies Inc. (OTC PINK:MDCE) Highlights Melanoma Detection App Development, AI Lifestyle App Launch, and Subsidiary Momentum
News Preview
MESA, ARIZONA / ACCESS Newswire / January 28, 2026 / Medical Care Technologies Inc. (OTC PINK:MDCE) ("MDCE" or the "Company"), a developer of innovative healthcare, lifestyle, and technology-driven solutions, today provided a comprehensive update to shareholders outlining significant progress across its core initiatives and subs...
Themefolio
Profiler
Peergroup
© PR Newswire
28.01.2026
GBT
LISTED
EURONEXT
Neue Indikation bei Kindern ab Geburt für Guerbets halbe Dosis GBCA, Elucirem™ (Gadopiclenol), von der Europäischen Kommission zugelassen
News Preview
VILLEPINTE, Frankreich, 28. Januar 2026 /PRNewswire/ -- Guerbet (FR0000032526 GBT), ein weltweit tätiger Spezialist für Kontrastmittel und Lösungen für die medizinische Bildgebung, freut sich, die Zulassung einer neuen Indikation für sein makrozyklisches Gadolinium-basiertes Kontrastmittel Elucirem™ (Gadopiclenol) bei Kindern ab der Geburt durch d...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
28.01.2026
TIVC
LISTED
NASDAQ
Tivic, BARDA Discuss Entolimod(TM) for Acute Radiation Syndrome at TechWatch Meeting
News Preview
January 26 Presentation highlighted Entolimod's potential to mitigate and prevent both gastrointestinal and hematopoietic injury from ionizing radiation exposureBARDA has requested a follow-up meeting to continue the discussion on the potential utility of Entolimod as a drug for the Strategic National StockpileShowcased clinical results, regulatory...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
28.01.2026
TNON
LISTED
NASDAQ
Tenon(R) Medical Issues Shareholder Letter and Provides Preliminary Revenue for the Fourth Quarter and Full Year 2025
News Preview
Fourth Quarter 2025 Revenue of $1.45 to $1.48 Million, representing growth of ~90% year over year.Full Year 2025 Revenue of $3.91 to $3.94 Million, representing growth of ~20% year over year. LOS GATOS, CA / ACCESS Newswire / January 28, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company redefining ca...
Themefolio
Profiler
Peergroup
© Newsfile
28.01.2026
COPN
LISTED
SIX
Invitation to Cosmo's Full Year 2025 Financial Results Webcast on 9 March 2026
News Preview
Dublin, Ireland--(Newsfile Corp. - January 28, 2026) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) announced today that it will publish its Full-Year 2025 results on Monday, 9 March 2026 at 7:00 am CET. Live conference call and audio webcast presentation: Cosmo invites investors...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
28.01.2026
AIML
LISTED
CSE
AIML Appoints Dr. Paul Dorian as Medical Innovation Architect and Head of the Medical Advisory Board
News Preview
World Renowned Cardiologist and Research Leader to Guide Clinical Strategy, Product Innovation, and AI-Driven Cardiac Diagnostics TORONTO, ON / ACCESS Newswire / January 28, 2026 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) is pleased to announce the appointment of Dr. Paul Dorian, MD, MSc...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.01.2026
IDIA
LISTED
SIX
Global expansion of Idorsia’s QUVIVIQ continues with EMS partnership for Latin America
News Preview
Ad hoc announcement pursuant to Art. 53 LR...
Themefolio
Profiler
Peergroup
© PR Newswire
28.01.2026
128940
LISTED
KOE
Hanmi Secures Export Deal with Mexican Partner Sanfer for GLP-1 Obesity Drug and More
News Preview
Hanmi Signs Exclusive Partnership with New Mexican Partner Laboratorios Sanfer, Covering Efpeglenatide and Diabetes Treatments SEOUL, South Korea, Jan. 27, 2026 /PRNewswire/ -- Hanmi is accelerating its global market entry with efpeglenatide, Korea's first domestically developed GLP-1 class obesity and metabolic disease treatment....
Themefolio
Profiler
Peergroup
© Globe Newswire
28.01.2026
ALT
LISTED
NASDAQ
Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock
News Preview
GAITHERSBURG, Md., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, announced today that it has entered into a securities purchase agreement with a new fundamental institutional investor for the purchase and sale of 17,045,454...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
28.01.2026
GENF
LISTED
LSE
Genflow Biosciences PLC Announces Administrative Approval of Grant & 2026 Priorities
News Preview
LONDON, UK / ACCESS Newswire / January 28, 2026 / THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF...
Themefolio
Profiler
Peergroup
© BusinessWire
28.01.2026
AGL
LISTED
NYSE
REMINDER: agilon health, inc. Investors With Significant Losses Must Act By March 2, 2026
News Preview
Kirby McInerney LLP reminds agilon health, inc. (“agilon” or the “Company”) (NYSE:AGL) investors of the March 2, 2026 deadline to seek the role of lead plaintiff in a pending federal securities class action. Courts do not consider applications filed after this deadline. The lead plaintiff oversees the litigation on behalf of the class and may infl...
Themefolio
Profiler
Peergroup
© PR Newswire
27.01.2026
VEEV
LISTED
NYSE
Branchenstudie zeigt: Schaffung einer Grundlage für KI hat für Konsumgüterunternehmen höchste Priorität
News Preview
82 % der Unternehmen stellen auf einheitliche Plattformen für standardisierte Daten und Prozesse um und bereiten sich auf KI vorBARCELONA, Spanien, 27. Januar 2026 /PRNewswire/ -- Ein neuer Branchenbericht zeigt, dass der Aufbau einer KI-fähigen Infrastruktur für Konsumgüterunternehmen (CPG) oberste Priorität hat. Der Bericht State of AI in Consum...
Themefolio
Profiler
Peergroup
© PR Newswire
27.01.2026
BDX
LISTED
NYSE
BD Board Declares Dividend, Authorizes 10 Million Additional Share Repurchases; BD Completed $250 Million Repurchase to Date in FY26
News Preview
FRANKLIN LAKES, N.J., Jan. 27, 2026 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has declared a quarterly dividend of $1.05 per common share, payable on March 31, 2026, to holders of record on March 10, 2026. The indicated annual dividend r...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.01.2026
BBIO
LISTED
NASDAQ
CORRECTING and REPLACING -- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
News Preview
PALO ALTO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by BridgeBio Pharma, Inc. (Nasdaq: BBIO), please note that some of the figures in the first paragraph were incorrect. The corrected release follows:...
Themefolio
Profiler
Peergroup
© BusinessWire
27.01.2026
ELMD
LISTED
XASE
Electromed, Inc. to Report Q2 Fiscal 2026 Financial Results on February 10, 2026
News Preview
Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that it will issue its financial results press release for the fiscal 2026 second quarter ended December 31, 2025, on Tuesday, February 10, 2026 after the close of the stock market. Company management will h...
Themefolio
Profiler
Peergroup
© BusinessWire
27.01.2026
EXEL
LISTED
NASDAQ
Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026
News Preview
Exelixis, Inc. (Nasdaq: EXEL) announced today that its fourth quarter and fiscal year 2025 financial results will be released on Tuesday, February 10, 2026 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the...
Themefolio
Profiler
Peergroup
© BusinessWire
27.01.2026
CDNA
LISTED
NASDAQ
CareDx to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
News Preview
CareDx, Inc. (Nasdaq: CDNA) - The Transplant Company™ —, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced the company will participate in the BTIG 13th Annual MedTech, Digital Health...
Themefolio
Profiler
Peergroup
© BusinessWire
27.01.2026
GILD
LISTED
NASDAQ
Gilead Sciences to Release Fourth Quarter & Full Year 2025 Financial Results on Tuesday, February 10, 2026
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2025 financial results and guidance will be released on Tuesday, February 10, 2026 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s fourth quarter and full year 2025 financial resul...
Themefolio
Profiler
Peergroup
© PR Newswire
27.01.2026
INNO
LISTED
CSE
Innocan Pharma Corporation Anticipates Listing on the NYSE American Stock Exchange with Concurrent Offering
News Preview
HERZLIYA, Israel and CALGARY, AB, Jan. 27, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies, today announced that, further to its press release dated January 2, 2026, it now an...
Themefolio
Profiler
Peergroup
© PR Newswire
27.01.2026
INNO
LISTED
CSE
Innocan Pharma Corporation Anticipates Listing on the NYSE American Stock Exchange with Concurrent Offering
News Preview
HERZLIYA, Israel and CALGARY, AB, Jan. 27, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies, today announced that, further to its press release dated January 2, 2026, it now an...
Themefolio
Profiler
Peergroup
© PR Newswire
27.01.2026
INNO
LISTED
CSE
Innocan Pharma Corporation Anticipates Listing on the NYSE American Stock Exchange with Concurrent Offering
News Preview
HERZLIYA, Israel and CALGARY, AB, Jan. 27, 2026 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies, today announced that, further to its press release dated January 2, 2026, it now anticipat...
Themefolio
Profiler
Peergroup
© PR Newswire
27.01.2026
JNJ
LISTED
NYSE
DARZALEX FASPRO®-based quadruplet regimen approved in the U.S. for newly diagnosed patients with multiple myeloma who are transplant ineligible
News Preview
Quadruplet regimen demonstrated significantly deeper and more durable responses, higher MRD negativity and improved progression-free survival versus a standard of care Approval marks the twelfth indication for DARZALEX FASPRO® and fifth in the newly diagnosed setting, underscoring its role as foundational therapy for both newly diagnosed and rel...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.01.2026
AIMI
LISTED
OTC
AIM ImmunoTech Announces Changes to Key Dates and Terms Related to Announced Rights Offering
News Preview
OCALA, Fla., Jan. 27, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, announced today changes to the previously announced key da...
Themefolio
Profiler
Peergroup
© BusinessWire
27.01.2026
MRK
LISTED
NYSE
Merck Announces Second-Quarter 2026 Dividend
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.85 per share of the company’s common stock for the second quarter of 2026. Payment will be made on April 7, 2026, to shareholders of record at the close of business on March 16, 2026.
About...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.01.2026
ADPT
LISTED
NASDAQ
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
News Preview
SEATTLE, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the following investor conferences....
Themefolio
Profiler
Peergroup
© Globe Newswire
27.01.2026
PACB
LISTED
NASDAQ
PacBio to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026
News Preview
MENLO PARK, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter and full year 2025 financial results on Thursday, February 12, 2026, at 5:00 pm Eastern Time....
Themefolio
Profiler
Peergroup
© PR Newswire
27.01.2026
STOK
LISTED
NASDAQ
Anchor Line Partners Supports Stoke Therapeutics' Growth by Securing a 98,500 Square-Foot Lease in Waltham, MA
News Preview
New Headquarters Will Support Company's Work to Deliver zorevunersen, a Potential Disease-Modifying Medicine, to Patients with Dravet Syndrome and Expansion of Research EffortsLease is One of the Largest in Greater Boston Life Sciences Over the Past YearWALTHAM, Mass., Jan. 27, 2026 /PRNewswire/ -- Anchor Line Partners, LLC and Northwood Investors...
Themefolio
Profiler
Peergroup
© PR Newswire
27.01.2026
GBT
LISTED
EURONEXT
New indication in children from birth for Guerbet's half-dose GBCA, Elucirem™ (Gadopiclenol) approved by European Commission
News Preview
VILLEPINTE, France, Jan. 27, 2026 /PRNewswire/ -- Guerbet (FR0000032526 GBT), a global specialist in contrast media and solutions for medical imaging, is delighted to announce the approval by European Commission of a new indication in children from birth for its macrocyclic high-relaxivity gadolinium-based contrast agent, Elucirem™ (gadopiclenol)...
Themefolio
Profiler
Peergroup
© PR Newswire
27.01.2026
1521
LISTED
HKSE
Frontage Europe Has Relocated Its Bioanalytical Laboratory and Further Expands Its Capabilities
News Preview
EXTON, Pa., Jan. 27, 2026 /PRNewswire/ -- We are pleased to communicate that Frontage Europe, a fully owned subsidiary of Frontage Laboratories Inc., has relocated its bioanalytical laboratory to consolidate all services in a 2,500 square meters facility close to Milan, Italy. This strategic decision represents a step forward to increase efficienc...
Themefolio
Profiler
Peergroup
© ActuNews
27.01.2026
ALTHX
LISTED
EURONEXT
THERANEXUS : BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITÉ CONFIÉ À PORTZAMPARC
News Preview
Lyon, France – 27 janvier 2026, 18h CET – THX Pharma (Theranexus), société biopharmaceutique innovante dans le traitement des maladies neurologiques rares, publie aujourd'hui le bilan semestriel de son contrat de liquidité confié à Portzamparc.
Au titre du contrat de liquidité confié...
Themefolio
Profiler
Peergroup
© BusinessWire
27.01.2026
BAYN
LISTED
XETR
Bayer Investing More Than $45M CAD to Build World-Class Canola Research and Development Facility in Canada
News Preview
Bayer Crop Science today announced an unprecedented $45+ million CAD investment to strengthen Canada’s leadership in canola innovation by establishing a cutting-edge canola innovation centre. Located in Winnipeg, Manitoba, the facility will house seed development work for canola, camelina and winter canola, focusing on trait integration, yield tri...
Themefolio
Profiler
Peergroup
© BusinessWire
27.01.2026
45520
LISTED
XJPX
JCR Pharmaceuticals to Present at the 22nd Annual WORLDSymposium™ 2026
News Preview
JCR Pharmaceuticals Co., Ltd. (TSE 4552; “JCR”), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, announced today that it will present data at the 22nd Annual WORLDSymposium™ 2026, held February 2-6, 2026, in San Diego, Calif. The poster presentations will demonstrate the potential benef...
Themefolio
Profiler
Peergroup
© PR Newswire
27.01.2026
MRK
LISTED
NYSE
Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks
News Preview
Issued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, Jan. 27, 2026 /PRNewswire/ -- Equity-Insider.com News Commentary – The global oncology therapy market is charging toward a massive $668 billion valuation by 2034, as a ruthless capital rotation finally rewards execution-ready platforms over the "hopes and dreams" of speculative discovery as...
Themefolio
Profiler
Peergroup
© PR Newswire
27.01.2026
MRK
LISTED
NYSE
Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks
News Preview
Issued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, Jan. 27, 2026 /CNW/ -- Equity-Insider.com News Commentary – The global oncology therapy market is charging toward a massive $668 billion valuation by 2034, as a ruthless capital rotation finally rewards execution-ready platforms over the "hopes and dreams" of speculative discovery assets[1]...
Themefolio
Profiler
Peergroup
© EQS Newswire
27.01.2026
VME
LISTED
XETR
MHH to Present Scientific Findings on Cold Plasma Therapy for Pulmonary Application at Press Conference in February 2026
News Preview
PRESS RELEASE
MHH to Present Scientific Findings on Cold Plasma Therapy for Pulmonary Application at Press Conference in February 2026
Rellingen, 27 January 2026 – On 12 February 2026, Hannover Medical School (MHH) – represented by Prof. Dr. Hortense Slevogt – plans to hold a press conference together with the team from the Helmholtz Centre for I......
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
